[go: up one dir, main page]

DE69904600D1 - Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamat - Google Patents

Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamat

Info

Publication number
DE69904600D1
DE69904600D1 DE69904600T DE69904600T DE69904600D1 DE 69904600 D1 DE69904600 D1 DE 69904600D1 DE 69904600 T DE69904600 T DE 69904600T DE 69904600 T DE69904600 T DE 69904600T DE 69904600 D1 DE69904600 D1 DE 69904600D1
Authority
DE
Germany
Prior art keywords
propylcarbamate
phosphono
aminophenyl
furanyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69904600T
Other languages
English (en)
Other versions
DE69904600T2 (de
Inventor
Gordon Armitage
David Searle
Hardev Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69904600D1 publication Critical patent/DE69904600D1/de
Application granted granted Critical
Publication of DE69904600T2 publication Critical patent/DE69904600T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69904600T 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamat Expired - Lifetime DE69904600T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound
PCT/EP1999/004991 WO2000004033A1 (en) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate

Publications (2)

Publication Number Publication Date
DE69904600D1 true DE69904600D1 (de) 2003-01-30
DE69904600T2 DE69904600T2 (de) 2003-11-13

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69904600T Expired - Lifetime DE69904600T2 (de) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamat

Country Status (47)

Country Link
US (3) US6514953B1 (de)
EP (2) EP1240903A3 (de)
JP (1) JP3437553B2 (de)
KR (1) KR100694721B1 (de)
CN (1) CN1188422C (de)
AP (1) AP2001002039A0 (de)
AR (1) AR019388A1 (de)
AT (1) ATE229964T1 (de)
AU (1) AU766056B2 (de)
BG (1) BG105253A (de)
BR (1) BRPI9912156B8 (de)
CA (1) CA2337857C (de)
CO (1) CO5090836A1 (de)
CZ (1) CZ300447B6 (de)
DE (1) DE69904600T2 (de)
DK (1) DK1098898T3 (de)
DZ (1) DZ2845A1 (de)
EA (1) EA003191B1 (de)
EE (1) EE200100038A (de)
ES (1) ES2189450T3 (de)
GB (1) GB9815567D0 (de)
GC (1) GC0000105A (de)
GE (1) GEP20033030B (de)
GT (1) GT199900111A (de)
HR (1) HRP20010046A2 (de)
HU (1) HU229700B1 (de)
ID (1) ID28070A (de)
IL (1) IL140824A (de)
IS (1) IS5808A (de)
JO (1) JO2114B1 (de)
MA (1) MA26660A1 (de)
MY (1) MY122323A (de)
NO (1) NO329676B1 (de)
NZ (1) NZ509291A (de)
OA (1) OA11706A (de)
PA (1) PA8477801A1 (de)
PE (1) PE20000869A1 (de)
PL (1) PL195736B1 (de)
PT (1) PT1098898E (de)
SK (1) SK285311B6 (de)
SV (1) SV1999000096A (de)
TN (1) TNSN99145A1 (de)
TR (1) TR200100111T2 (de)
TW (1) TWI245770B (de)
WO (1) WO2000004033A1 (de)
YU (1) YU3401A (de)
ZA (1) ZA200100417B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ES2307533T3 (es) * 1999-10-06 2008-12-01 Tibotec Pharmaceuticals Ltd. Hexahidrofuro(2,3)furan-3-il-n-(3-((1,3-benzodioxol-5-ilsulfonil)(is obuti)amino)-1-bencil-2-hidroxipropil carbamato como inhibidor de la proteasa retroviral.
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
DK1560584T3 (da) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
CN101041669A (zh) * 2002-04-26 2007-09-26 吉里德科学公司 非核苷逆转录酶抑制剂
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
CA2519429C (en) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
EP1620109A2 (de) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhbitor phosphonat konjugate
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20080234288A1 (en) * 2003-09-30 2008-09-25 Kenneth Alan Simmen Hcv Inhibiting Sulfonamides
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7273717B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
MXPA06006899A (es) 2003-12-22 2006-09-04 Gilead Sciences Inc Derivados de carbovir y abacavir 4'-sustituidos asi como compuestos relacionados con actividad antiviral de virus de inmunodeficiencia humana y virus de la hepatitis c.
KR101299399B1 (ko) 2004-06-04 2013-08-22 아피늄 파마슈티컬스, 인크. 치료제, 및 그의 제조 및 사용 방법
HRP20070078A2 (hr) 2004-07-27 2007-05-31 Gilead Sciences Fosfonatni analozi spojeva koji inhibiraju hiv
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP2125802A4 (de) * 2007-02-16 2014-08-20 Debiopharm Int Sa Salze, prodrugs und polymorphe von fab-i-inhibitoren
CN102816111B (zh) 2007-03-12 2014-08-06 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
EP2262538B1 (de) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-aminosäure konjugate
PT2307435E (pt) 2008-07-08 2012-09-19 Gilead Sciences Inc Sais de compostos inibidores de vih
CA2998344C (en) * 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
EP2440249A2 (de) 2009-06-12 2012-04-18 Nektar Therapeutics Kovalente konjugate mit einem protease-inhibitor, einem wasserlöslichen nicht-peptidischen oligomer und einem lipophilen teil
WO2011001383A1 (en) 2009-06-30 2011-01-06 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
AU2010296846B2 (en) * 2009-09-16 2013-11-28 Sun Pharmaceutical Industries Limited Process for the preparation of fosamprenavir calcium
EP2507250A1 (de) * 2010-01-07 2012-10-10 Pliva Hrvastka D.O.O. Feste formen von fosamprenavir-calciumsalz und verfahren zu deren herstellung
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (en) 2010-03-19 2011-09-22 Lupin Limited Ammonium, calcium and tris salts of fosamprenavir
US20130211108A1 (en) 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス, インコーポレイテッド L−オルニチンフェニルアセテートを製造するための方法
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (en) 2010-12-21 2012-06-28 Lupin Limited Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
JP2014513044A (ja) * 2011-02-10 2014-05-29 マイラン ラボラトリーズ リミテッド ホスアンプレナビルカルシウム結晶およびその調製方法
WO2013011485A1 (en) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Process for the preparation of sulfonamides useful as retroviral protease inhibitors
US9233943B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
BR122021020778B1 (pt) 2012-06-19 2022-07-12 Debiopharm International Sa Derivados de pró-fármaco de (e)-n-metil-n-((3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida
CN107206021B (zh) 2014-11-24 2021-09-03 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
SI3419628T1 (sl) 2016-02-26 2021-03-31 Debiopharm International Sa Zdravilo za zdravljenje infekcij diabetičnega stopala
JP7126520B2 (ja) 2017-05-11 2022-08-26 オセラ セラピューティクス, インコーポレイテッド L-オルニチンフェニルアセテートを製造する方法
WO2019027920A1 (en) 2017-08-01 2019-02-07 Gilead Sciences, Inc. CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
PH12021551922A1 (en) 2019-02-14 2022-05-23 Debiopharm Int Sa Afabicin formulation, method for making the same
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
HUP0101598A3 (en) * 1997-12-24 2002-08-28 Vertex Pharmaceuticals Inc Cam Prodrugs of aspartyl protease inhibitors and medicaments containing them
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
CA2346131C (en) * 1998-11-04 2013-01-15 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US6642237B1 (en) * 1999-11-24 2003-11-04 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

Also Published As

Publication number Publication date
ES2189450T3 (es) 2003-07-01
TR200100111T2 (tr) 2002-02-21
BR9912156A (pt) 2001-04-10
GEP20033030B (en) 2003-07-25
CN1188422C (zh) 2005-02-09
NO20010282L (no) 2001-03-07
PL345620A1 (en) 2002-01-02
KR100694721B1 (ko) 2007-03-15
GB9815567D0 (en) 1998-09-16
HU229700B1 (en) 2014-05-28
IL140824A0 (en) 2002-02-10
YU3401A (sh) 2005-06-10
PE20000869A1 (es) 2000-09-08
EP1098898B1 (de) 2002-12-18
CA2337857A1 (en) 2000-01-27
US20030096795A1 (en) 2003-05-22
US6514953B1 (en) 2003-02-04
EA003191B1 (ru) 2003-02-27
PL195736B1 (pl) 2007-10-31
CZ2001219A3 (cs) 2001-07-11
JP3437553B2 (ja) 2003-08-18
TWI245770B (en) 2005-12-21
NZ509291A (en) 2003-05-30
BRPI9912156B8 (pt) 2021-05-25
GT199900111A (es) 2001-01-05
EE200100038A (et) 2002-06-17
BG105253A (en) 2001-12-29
SK762001A3 (en) 2001-10-08
JO2114B1 (en) 2000-05-21
MY122323A (en) 2006-04-29
ATE229964T1 (de) 2003-01-15
HUP0103432A2 (hu) 2002-04-29
PT1098898E (pt) 2003-04-30
HK1034261A1 (en) 2001-10-19
IL140824A (en) 2004-09-27
NO329676B1 (no) 2010-11-29
CN1324363A (zh) 2001-11-28
ID28070A (id) 2001-05-03
SK285311B6 (sk) 2006-10-05
DZ2845A1 (fr) 2003-12-01
CZ300447B6 (cs) 2009-05-20
ZA200100417B (en) 2002-02-27
PA8477801A1 (es) 2000-05-24
MA26660A1 (fr) 2004-12-20
SV1999000096A (es) 2000-07-06
EP1240903A3 (de) 2003-02-12
NO20010282D0 (no) 2001-01-17
AU766056B2 (en) 2003-10-09
GC0000105A (en) 2005-06-29
TNSN99145A1 (fr) 2005-11-10
CO5090836A1 (es) 2001-10-30
AU5037999A (en) 2000-02-07
BRPI9912156B1 (pt) 2016-07-26
EA200100053A1 (ru) 2001-08-27
HUP0103432A3 (en) 2003-01-28
IS5808A (is) 2001-01-12
HRP20010046A2 (en) 2002-02-28
EP1098898A1 (de) 2001-05-16
CA2337857C (en) 2011-01-25
DE69904600T2 (de) 2003-11-13
JP2003521447A (ja) 2003-07-15
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
OA11706A (en) 2005-01-13
WO2000004033A1 (en) 2000-01-27
DK1098898T3 (da) 2003-04-07
AP2001002039A0 (en) 2001-03-31
EP1240903A2 (de) 2002-09-18
AR019388A1 (es) 2002-02-13

Similar Documents

Publication Publication Date Title
DE69904600D1 (de) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamat
ATE289212T1 (de) Phiole für implantat
ITMI982247A0 (it) Procedimento per impermeabilizzare la pelle ottenuta mediante tale procedimento
DE69840203D1 (de) Vefahren zur Datenkompression
DE59806274D1 (de) Anordnung zur übertragung von programmen
BR9603540A (pt) n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida
AU5818100A (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzy -2-(phosphonooxy)propylcarbamate
FI973105L (fi) Menetelmä (4,10-diasetoksi-2alfa-bentsoyylioksi-5beta,20-epoksi,1,7beta-dihydroksi-9-oksotaks-11-en-13alfa-yyli)-(2R,3S)-3-bentsoyyliamino-3-fenyyli-2-hydroksipropionaattitrihydraatin valmistamiseksi
DE69934046D1 (de) Beta-glucooligosaccharide zur beschleunigung von calciumaufnahme
FR2763498B1 (fr) Endoscope, en particulier mediastinoscope
SI1098898T1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
ES1033492Y (es) Mojon de limitacion vial, amovible.
WO2004091280A3 (en) Pharmaceutical compositions
ES1036075Y (es) Consola.
HN1999000113A (es) (3s) tetrahidro - 3 - funaril (15, 2r) - 3 - [[4 - aminofenil) sulfonil)] (isobutil) amino] - 1 - bencil - 2 (fosfonooxi) propilcarbamato de calcio.
SE9802165D0 (sv) Visarinstrument för fordon
ITBO980069A0 (it) Piattaforma rotante per autoveicoli.
AU8463098A (en) Process for preparing (2r,3s)-3-(substituted or unsubstituted phenyl)glycidamidecompounds by asymmetric amidation
IT1297650B1 (it) Strumento chirurgico per interventi sul cristallino catarattoso - scalliper
ES1030098Y (es) Tapa-casquillo nivelador, para somieres de ballestas.
ES1037174Y (es) Portainstrumental quirurgico.
ES1039404Y (es) Flauta de embolo transparente.
ITBO970443A0 (it) Tovagliolino mappa per parco giochi.
FR2766908B1 (fr) Module de ventilation, notamment pour veranda
UA2710S (uk) Ковпачок до флаконів

Legal Events

Date Code Title Description
8364 No opposition during term of opposition